Pfizer and BioNtech’s COVID-19 vaccine showed 94 percent efficacy in a real-world study conducted in Israel, involving 1.2 million people. The findings, published in the New England Journal of Medicine, showed that the vaccine performed as it had during the clinical trial.
In this study, all individuals who were newly vaccinated during the period from December 20, 2020 to February 1, 2021 matched the unvaccinated controls in a ratio of 1: 1, according to the demographic and clinical characteristics. Each study group consisted of 596,618 people.
Results of the study included SARS-Cove-2 infection, symptomatic Kovid-19, Kovid-19 related hospitalization, critical illness and death.
If you have any concerns or complaints regarding this article, please let us know and the article will be removed soon.